Following the close of the deal, Opko's diagnostic services will be merged with Bio-Reference's operations.
The contracts with Stratose, Three Rivers Provider Network, and Fortified Provider Network provide coverage for Opko's testing services.
The deal is still subject to other closing conditions including the approval of BRL's shareholders.
The firm said that revenues per patient were up 3 percent, while the number of patients served grew 8 percent.
Opko plans to leverage BRL's national marketing, sales, and distribution resources to enhance the sale of its blood-based 4Kscore test for aggressive prostate cancer.
NEW YORK (GenomeWeb) – Opko Health said this week that it has launched sales of its 4Kscore prostate cancer risk test in additional European territories.
Opko Health this week announced the launch of its 4Kscore prostate cancer test, which it will offer out of its Nashville, Tenn.-based CLIA lab.
Somalogic said this week that it has named Dan Muehl as chief financial officer.
Opko Health has appointed Greg Stanley vice president of sales and marketing for its global diagnostics business unit.
Opko Health said this week that it has purchased Uruguayan pharmaceutical company Laboratorio Arama de Uruguay Limited.
Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.
St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.
St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.
In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.